| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 7.23 Billion |
| Market Size (2030) | USD 16.26 Billion |
| CAGR (2025 - 2030) | 17.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Next-Generation Sequencing (NGS) Services Market Analysis
The Next-Generation Sequencing Services Market size is estimated at USD 7.23 billion in 2025, and is expected to reach USD 16.26 billion by 2030, at a CAGR of 17.60% during the forecast period (2025-2030).
Next-generation sequencing (NGS) services refer to a suite of laboratory and bioinformatics solutions that enable the sequencing of DNA or RNA at unprecedented speed, scale, and accuracy. These services leverage advanced sequencing technologies to decode organisms' genetic information, providing detailed insights into their genomic, transcriptomic, and epigenomic landscapes. The next-generation sequencing (NGS) services market is driven by the rising prevalence of genetic disorders and cancer, rising demand for personalized medicine, and technological advancements during the forecast period.
Next-generation sequencing (NGS) services have become instrumental in advancing personalized medicine, creating significant market opportunities. The NGS services market is primarily driven by increasing demand for personalized healthcare solutions, genetic testing, and diagnostic services.
For instance, according to an article published in the National Institutes of Health in March 2024, using NGS to diagnose single-gene and Mendelian disorders is a cornerstone of personalized medicine. Rapid sequencing allows for comprehensive testing of genes associated with rare diseases, such as hereditary ataxia and amyotrophic lateral sclerosis. Programs like the Centers for Mendelian Genomics leverage NGS technologies to uncover mutations responsible for poorly understood conditions. For example, whole exome sequencing (WES) identified mutations in the DIAPH1 gene associated with hearing loss-thrombocytopenia syndrome. Similarly, WES has revealed susceptibility loci for conditions like severe hemophilia A, offering insights into disease mechanisms and guiding targeted treatments. Thus, the demand for personalized medicine represents a significant force for market growth during the forecast period.
Furthermore, the next-generation sequencing (NGS) services market has witnessed significant growth due to ongoing technological advancements, particularly the emergence of third-generation sequencing technologies.
For instance, according to a study published in the Journal of Biology in July 2023, PacBio Sequencing used single-molecule, real-time (SMRT) technology to sequence DNA fragments up to tens of kilobases long. This technology enables highly accurate characterization of genomes, epigenomes, and transcriptomes. Moreover, it also highlighted that Oxford Nanopore Sequencing employs nanopore technology, wherein a single-stranded DNA molecule passes through a nanopore and electrical current variations are used to decode the DNA sequence. These innovations are expected to continue driving market expansion, enabling a broader range of applications and enhancing the value of genomic insights across industries.
Additionally, the high prevalence of chronic diseases such as cancer in the countries studied fuels the demand for next-generation sequencing services and contributes to segment growth. For instance, according to 2023 statistics published by the Red Espanola de Registros de Cancer, about 31,282 lung cancer cases were diagnosed in Spain in 2023, compared to 29,188 cases in 2022. Thus, the increase in lung cancer cases significantly contributes to the market’s growth.
Moreover, in February 2023, Cancer Research United Kingdom stated that the number of new cancers combined yearly in the United Kingdom will rise from around 420,000 cases in 2023-2025 to around 506,000 cases by 2038-2040. Therefore, NGS-based comprehensive genomic profiling (CGP) enables the identification of actionable mutations across a wide range of cancers, further propelled the integration of NGS services in cancer care, which will significantly fuel the market’s growth during the forecasted period.
These factors will contribute to the next-generation sequencing (NGS) services market’s growth. However, the high cost of infrastructure and lack of skilled professionals restrain market growth.
Next-Generation Sequencing (NGS) Services Market Trends
Drug Discovery & Development Segment is Expected to Witness Significant Growth Over the Forecast Period
The integration of next-generation sequencing (NGS) into drug discovery and development is driven by its ability to efficiently analyze vast genetic datasets and uncover actionable insights for targeted therapies. Its application in high-prevalence cancers, such as non-small cell lung cancer (NSCLC), colorectal cancer, and melanoma, exemplifies its transformative potential.
For instance, a study published in Cancer Genetics and Oncogenomics in July 2024 highlighted NGS as a cornerstone in clinical oncology, underscored by initiatives such as the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). These projects leverage NGS to map genetic mutations across various cancers, facilitating the identification of driver mutations and novel therapeutic targets. Furthermore, comprehensive genomic profiling (CGP) based on NGS platforms has expanded the scope of cancer testing, accelerating the discovery of precision-based drugs. Therefore, the growing adoption of NGS platforms for drug discovery and development will propel segmental growth in the upcoming years.
In addition, in drug development, the clinical impact of NGS is evident in its ability to guide the development of targeted therapies and improve patient outcomes. For example, a study published in JCO Precision Oncology in June 2023 reviewed 31 studies on advanced cancer patients receiving NGS-based treatment. The findings demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) for patients matched to targeted therapies. Additionally, the versatility of NGS panels enables their application across diverse tumor types, including NSCLC, colorectal cancer, and melanoma. Such advancements have redefined precision oncology and positioned NGS as a critical tool in the drug development pipeline, driving the market’s growth.
Furthermore, the expanded recommendations for NGS further highlight its growing role in advanced cancer diagnostics and therapeutic development. For instance, in May 2024, the European Society for Medical Oncology (ESMO) Precision Medicine Working Group (PMWG) updated its recommendations for NGS testing. Initially focused on metastatic cancers like non-squamous NSCLC, prostate cancer, and ovarian cancer, the recommendations now include advanced breast cancer, gastrointestinal stromal tumors (GIST), sarcomas, thyroid cancers, and cancers of unknown primary (CUP). These updates emphasize the increasing reliance on NGS for identifying tumor-agnostic alterations and rare oncogenic drivers, providing valuable insights for drug discovery and personalized medicine. Thus, the expanding recommendations for NGS underscore its pivotal role in revolutionizing drug discovery within the NGS services market and it will boost the market’s growth in the upcoming years.
Hence, with the increasing advancement in NGS and increasing adoption of NGS for drug discovery and development, the studied segment is expected to witness notable growth over the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Dominate the Next-Generation Sequencing (NGS) Services Market
The next-generation sequencing (NGS) services market in North America is poised for significant growth, driven by investments in addressing chronic disorders, government initiatives to enhance biotechnology infrastructure, expansion of drug manufacturing facilities and regulatory support further highlight the region's commitment to advancing NGS technologies for improved diagnostics and therapeutic development.
Further, the increasing burden of other chronic diseases like Alzheimer’s is further contributing to the market's growth. For instance, as per 2024 Alzheimer's Disease Facts and Figures, an estimated 6.9 million individuals aged 65 years and above will be living with Alzheimer’s in 2024 in the United States.
Also, according to 2024 data published by the American Cancer Society, about 152,810 new cases of colorectal cancer are expected to be diagnosed in the United States in 2024, compared to 153,020 colorectal cases diagnosed in 2023. Thus, the increasing prevalence of chronic disorders, such as Alzheimer's disease and cancer, is expected to drive the segment over the forecast period.
Moreover, the FDA’s approval of the Invitae Common Hereditary Cancers Panel in November 2023 marked a milestone in the next-generation sequencing (NGS) services market in the United States. This test analyzes blood samples to detect inherited genetic changes that increase the risk of cancers such as breast, ovarian, and colorectal cancer. By leveraging next-generation sequencing, it examines genes like BRCA1, BRCA2, and Lynch syndrome-related genes (MLH1, MSH2, MSH6, PMS2). The panel achieved over 99% accuracy in validating genetic changes, making it a reliable tool for assessing hereditary cancer risks.
Therefore, the FDA’s introduction of a new regulatory classification for such multigene panel tests ensures rigorous safety and efficacy validation. As the prevalence of cancer continues to rise, the demand for accurate, comprehensive genetic testing tools is expected to grow, thus impacting the market in the country.
Additionally, increasing government initiatives and substantial investments in biotechnology research are expected to drive the growth of the next-generation sequencing (NGS) services market in Canada. Furthermore, expanding drug manufacturing facilities in Canada is fueling market growth. For instance, in March 2023, the Canadian government committed CAD 80.5 million (USD 59 million) to the Canadian Critical Drug Initiative, supporting the establishment of a 40,000-square-foot manufacturing facility in Edmonton by Applied Pharmaceutical Innovation in collaboration with the Li Ka Shing Applied Virology Institute. This funding is expected to enhance drug research, commercialization, and production, further driving the need for efficient next-generation sequencing (NGS) services solutions, thereby driving the market’s growth during the study period.
Consequently, the rising burden of chronic diseases, increasing regulatory approvals, and expanding regional drug manufacturing facilities are set to propel the North American market for next-generation sequencing (NGS) services.
Get Analysis on Important Geographic Markets
Download PDF
Next-Generation Sequencing (NGS) Services Industry Overview
The next-generation sequencing (NGS) services market is highly fragmented, characterized by numerous players, ranging from large global companies to smaller regional firms, each offering a diverse range of solutions. To strengthen their market position and expand their footprint, key participants are increasingly adopting strategic initiatives such as acquisitions and collaborations with other organizations. The major players in the market include Illumina, Inc., PerkinElmer, Inc., Eurofins Scientific SE, BGI, Macrogen, Inc., Qiagen N.V., Genewiz, Inc., Genotypic Technology Pvt. Ltd., DNA Link, Inc., Takara Bio Inc., Personalis, Inc., LGC Limited, Scigenom Labs Pvt. Ltd., Novogene Corporation., among others.
Next-Generation Sequencing (NGS) Services Market Leaders
-
Illumina, Inc.
-
PerkinElmer, Inc.
-
BGI
-
Eurofins Scientific SE
-
Qiagen N.V.
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Next-Generation Sequencing (NGS) Services Market News
- September 2024: NeoGenomics, Inc., an oncology testing services company, presented three significant studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. The data to be presented highlights crucial insights into circulating tumor DNA (ctDNA) analysis and next-generation sequencing (NGS), focusing on their roles in early diagnosis and optimizing treatment strategies for oncology patients.
- July 2023: The University of the Free State's Next Generation Sequencing (UFS-NGS) Unit, part of the Faculty of Health Sciences, hosted a successful Data & Bioinformatics Workshop at its Bloemfontein Campus. The workshop aimed to equip participants with essential bioinformatics skills for analyzing NGS data, focusing on whole genome sequencing, 16S/ITS metagenomics, and microbial metagenomics. This initiative highlights the growing emphasis on developing expertise in NGS data analysis, a critical component in leveraging the full potential of NGS services for research and clinical applications.
Next-Generation Sequencing (NGS) Services Industry Segmentation
Next-generation sequencing (NGS) services provide sequencing platforms and expertise to decode DNA or RNA with high precision and efficiency.
The next-generation sequencing (NGS) services market is segmented into service type, technology, application, end user, and geography. By service type, the market is segmented into human genome sequencing services, single-cell sequencing services, microbial genome-based sequencing services, gene regulation services, and other service type. By technology, the market is segmented into sequencing-by-synthesis (SBS), ion semiconductor sequencing, nanopore sequencing, and single-molecule real-time (SMRT) sequencing. By application, the market is segmented into clinical diagnostics, drug discovery & development, agriculture & environmental, biotechnology & genetic research and other applications. By end user, the market is segmented into hospitals & clinics, pharmaceutical & biotech companies, clinical diagnostic laboratories, academic and research institutions, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The report also offers the market size and forecasts for 17 countries across the region. For each segment, the market sizing and forecasts have been done on the basis of value (USD).
| By Service Type | Human Genome Sequencing Services | ||
| Single Cell Sequencing Services | |||
| Microbial Genome-based Sequencing Services | |||
| Gene Regulation Services | |||
| Other Service Type | |||
| By Technology | Sequencing-by-Synthesis (SBS) | ||
| Ion Semiconductor Sequencing | |||
| Nanopore Sequencing | |||
| Single-Molecule Real-Time (SMRT) Sequencing | |||
| By Application | Clinical Diagnostics | ||
| Drug Discovery & Development | |||
| Agriculture & Environmental | |||
| Biotechnology & Genetic Research | |||
| Other Applications | |||
| By End User | Hospitals & Clinics | ||
| Pharmaceutical & Biotech Companies | |||
| Clinical Diagnostic Laboratories | |||
| Academic and Research Institutions | |||
| Other End Users | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Next-Generation Sequencing (NGS) Services Market Research FAQs
How big is the Next-Generation Sequencing Services Market?
The Next-Generation Sequencing Services Market size is expected to reach USD 7.23 billion in 2025 and grow at a CAGR of 17.60% to reach USD 16.26 billion by 2030.
What is the current Next-Generation Sequencing Services Market size?
In 2025, the Next-Generation Sequencing Services Market size is expected to reach USD 7.23 billion.
Who are the key players in Next-Generation Sequencing Services Market?
Illumina, Inc., PerkinElmer, Inc., BGI, Eurofins Scientific SE and Qiagen N.V. are the major companies operating in the Next-Generation Sequencing Services Market.
Which is the fastest growing region in Next-Generation Sequencing Services Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Next-Generation Sequencing Services Market?
In 2025, the North America accounts for the largest market share in Next-Generation Sequencing Services Market.
What years does this Next-Generation Sequencing Services Market cover, and what was the market size in 2024?
In 2024, the Next-Generation Sequencing Services Market size was estimated at USD 5.96 billion. The report covers the Next-Generation Sequencing Services Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Next-Generation Sequencing Services Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
